Treatment of hidradenitis suppurativa

Abstract

Hidradenitis suppurativa can be treated by administering a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α.

What is claimed is: 
     
         1 . A method of treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-interleukin-1α antibody effective to treat a symptom of hidradenitis suppurativa in the subject. 
     
     
         2 . The method of  claim 1 , wherein the anti-interleukin-1α antibody is a monoclonal antibody. 
     
     
         3 . The method of  claim 2 , wherein the monoclonal antibody is an IgG1. 
     
     
         4 . The method of  claim 3 , wherein the monoclonal antibody comprises at least one of complementarity determining regions (CDRs) of MABp1. 
     
     
         5 . The method of  claim 4 , wherein the monoclonal antibody comprises all of the CDRs of MABp1. 
     
     
         6 . The method of  claim 5 , wherein the monoclonal antibody is MABp1. 
     
     
         7 . The method of  claim 1 , wherein the subject receives 1-20 mg/kg body weight of the anti-interleukin-1α antibody. 
     
     
         8 . The method of  claim 1 , wherein the pharmaceutical composition is for repeated administration, wherein the repeated administration is semi-weekly, weekly, biweekly, tri-weekly, semi-monthly, once every three weeks, monthly, bi-monthly. 
     
     
         9 . The method of  claim 1 , wherein the Ka of the antibody is at least 1×10 9  M −1 . 
     
     
         10 . The method of  claim 1 , wherein the subject's Hidradenitis Suppurativa Clinical Response (HiSCR) score is improved after administration of the pharmaceutical composition. 
     
     
         11 . The method of  claim 1 , wherein the median size of the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition. 
     
     
         12 . The method of  claim 1 , wherein the subject's pain associated with the subject's hidradenitis suppurativa lesions is reduced after administration of the pharmaceutical composition. 
     
     
         13 . The method of  claim 1 , wherein the subject's time to new hidradenitis suppurativa lesions is increased after administration of the pharmaceutical composition. 
     
     
         14 . The method of  claim 1 , wherein hidradenitis suppurativa in the human subject has failed to resolve after treatment with tumor necrosis factor alpha inhibitors. 
     
     
         15 . The method of  claim 1 , wherein the treatment reduces the number and/or size of inflammatory lesions. 
     
     
         16 . The method of  claim 15 , wherein the inflammatory lesion is selected from the group consisting of a nodule, an abscess, and a draining fistula. 
     
     
         17 . The method of  claim 1 , further comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti- Staphylococcus aureus  (anti- S. aureus ) antibody. 
     
     
         18 . The method of claim17, wherein the anti- S. aureus  antibody comprises a Fab region paratope that specifically binds to  S. aureus  protein A (SpA) and an Fc region that does not specifically bind SpA.